An HIV Vaccine Could Hit The Market As Early As 2021, Experts Say
Experts working on developing a vaccine for HIV say they are optimistic about clinical trials and believe an end product could be ready as soon as 2021, according to LGBTQ Nation.
There are currently three different trials in the works, and Dr. Susan Buchbinder, who chairs two of them, told NBC News this week that this is “perhaps one of the most optimistic moments we have been in.”
“We have three vaccines currently being tested in efficacy trials, and it takes quite a bit to actually be promising enough in the earlier stages of trials to move you forward into an efficacy study,” she said.
Two of the trials, Imbokodo and Mosaico, use “mosaic” immunogens “to target a wide number of global HIV strains” in an approach that “could give a broader coverage than HVTN 702, which focuses on an HIV strain typically found in southern Africa,” according to Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases (NIAID).
HVTN 702, which is the third trial underway, is “based on an even older vaccine candidate, RV144,” which “lowered the rate of HIV infections by about 30% – a good result, but not effective enough to be considered a success.”
This new trial was launched in 2016 in South Africa, with results expected as early as the end of next year.
“If one or more of these vaccines look good – have a 50 to 60 percent efficacy – I think that’s going to be the game changer for turning the epidemic around,” Fauci said.